{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:38:51Z","timestamp":1761896331672},"reference-count":24,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3960\/jslrt.56.34","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T20:59:17Z","timestamp":1466629157000},"page":"34-42","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014"],"prefix":"10.3960","volume":"56","author":[{"given":"Noriaki","family":"Kawano","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenobu","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Trauma and Critical Care Center, Faculty of Medicine, University of Miyazaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Research Unit for Human Disease Models, RIKEN Research Center f or Allergy and Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Fialkow PJ, Jacobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage. Am J Med 63:125-130, 1977","DOI":"10.1016\/0002-9343(77)90124-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Faderl S1, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, <i>et al<\/i>.: The biology of chronic myeloid leukemia. N Engl J Med 341:164-172, 1999","DOI":"10.1056\/NEJM199907153410306"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293, 1973","DOI":"10.1038\/243290a0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, <i>et al<\/i>.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003","DOI":"10.1056\/NEJMoa022457"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 O\u2019brien SG, Guilhot F, Goldman JM: International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia I chronic phase (CMLCP) treated with imatinib (IM). Blood (ASH Annual Meeting Abstracts) 112:186, 2008 [abstract]","DOI":"10.1182\/blood.V112.11.186.186"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, <i>et al<\/i>.: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010","DOI":"10.1056\/NEJMoa1002315"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Saglio G, Kim DW, Issaragrisil S, Coutre PL, Etienne G, <i>et al<\/i>.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010","DOI":"10.1056\/NEJMoa0912614"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, <i>et al<\/i>.: Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 35:585-590, 2011","DOI":"10.1016\/j.leukres.2010.10.027"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, <i>et al<\/i>.: Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol 99:141-153, 2014","DOI":"10.1007\/s12185-013-1470-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, <i>et al<\/i>.: Nilotinib as frontline therapy for patients with newly diagnosed Ph<sup>+<\/sup> chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol 93:624-632, 2011","DOI":"10.1007\/s12185-011-0841-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, <i>et al<\/i>.: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006","DOI":"10.1182\/blood-2006-02-005686"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, <i>et al<\/i>.: Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789-799, 1984","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Deininger MW : Management of early stage disease. Hematology (Am Soc Hematol Educ Program) 174-182, 2005","DOI":"10.1182\/asheducation-2005.1.174"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Hu B, Savani BN: Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Eur J Haematol 93:179-186, 2014","DOI":"10.1111\/ejh.12356"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, <i>et al<\/i>.: European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci 105:105-109, 2014","DOI":"10.1111\/cas.12321"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Andrikovics H, Nahajevszky S, Szilv\u00e1si A, Bors A, Ad\u00e1m E, <i>et al<\/i>.: First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. Hematol Oncol 25:143-147, 2007","DOI":"10.1002\/hon.822"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Gu\u00e9rin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, <i>et al<\/i>.: Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.Curr Med Res Opin 30:2317-2328, 2014","DOI":"10.1185\/03007995.2014.944973"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kawaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, <i>et al<\/i>.: Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol 89:642-648, 2009","DOI":"10.1007\/s12185-009-0315-4"},{"key":"19","unstructured":"19 Takahashi N: Chronic myelogenous leukemia: management of treatment-related adverse events. Rinsho Ketsueki 53:1581-1588, 2012 (<i>in Japanese<\/i>)"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Jabbour E, Kantarjian H, O\u2019Brien S, Rios MB, Abruzzo L, <i>et al<\/i>.: Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107:480-482, 2006","DOI":"10.1182\/blood-2005-05-1816"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Alimena G, Breccia M, Latagliata R, Carmosino I, Russo E, <i>et al<\/i>.: Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 107:1008-1013, 2006","DOI":"10.1002\/cncr.22046"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 O\u2019Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, <i>et al<\/i>.: Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 12:1590-1610, 2014","DOI":"10.6004\/jnccn.2014.0159"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Palani R, Milojkovic D, Apperley JF: Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 94 (Suppl 2):S167-176, 2015","DOI":"10.1007\/s00277-015-2317-z"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/56\/1\/56_34\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T18:51:57Z","timestamp":1600800717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/56\/1\/56_34\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.56.34","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}